The prevalence of contraindications to the use of metformin

Canadian Journal of Diabetes

Volumn 28, Issue 4, 2004, Pages 380-384

  Khandwala, Hasnain M ^a,b  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b ROYAL UNIVERSITY HOSPITAL   (Canada)

Author keywords

Congestive heart failure; Hepatic insufficiency; Lactic acidosis; Metformin; Renal insufficiency

Indexed keywords

METFORMIN;

ARTICLE; CANADA; CONGESTIVE HEART FAILURE; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG WITHDRAWAL; HOSPITAL ADMISSION; HUMAN; LACTIC ACIDOSIS; MAJOR CLINICAL STUDY; PREVALENCE; RISK FACTOR; UNIVERSITY HOSPITAL;

EID: 28844450339     PISSN: 14992671     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Lucis OJ. The status of metformin in Canada. Can Med Assoc J. 1983;128:24-26.
2. Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996;334:574-579.
3. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin dependent diabetes mellitus. The Multicenter Metformin Study Group N Engl J Med. 1995;333:541-549.
4. Aguilar C, Reza A, Garcia JE, et al. Biguanide related lactic acidosis: incidence and risk factors. Arch Med Res. 1992;23:19-24.
5. Stang MR, Wysowski DK, Butler-Jones D. Incidence of lactic acidosis in metformin users. Diabetes Care. 1999;22:925-927.
6. Wiholm BE, Myrhed M. Metformin-associated lactic acidosis in Sweden 1977-1991. Eur J Clin Pharmacol. 1993;44:589-591.
7. Misbin RI, Green L, Stadel BV, et al. Lactic acidosis in patients with diabetes treated with metformin. N Engl J Med. 1998;338:265-266.
8. Abbasi AA, Kasmikha R, Sotingeanu DG. Metformin-induced lacticacidemia in patients with type 2 diabetes mellitus. Endocr Pract. 2000;6:442-446.
9. Misbin RI. Phenformin-associated lactic acidosis: pathogenesis and treatment. Ann Intern Med. 1977;87:591-595.
10. Sulkin TV, Bosman T, Krentz AJ. Contraindications to metformin therapy in patients with NIDDM. Diabetes Care. 1997;20:925-928.
11. Calabrese AT, Coley KC, DaPos SV, et al. Evaluation of prescribing practices: risk of lactic acidosis with metformin therapy. Arch Intern Med. 2002;162:434-437.
12. Horlen C, Malone R, Bryant B, et al. Frequency of inappropriate metformin prescriptions. JAMA. 2002;287:2504-2505.
13. Holstein A, Nahrvold D, Hinze S, et al. Contra-indications to metformin therapy are largely disregarded. Diabet Med. 1999;16:692-696.
14. Brown JB, Pedula K, Barzilay J, et al. Lactic acidosis rates in type 2 diabetes. Diabetes Care. 1998;21:1659-1663.
15. Erratum in: Diabetes Care. 1998;21:2203.
16. Salpeter SR, Greyber E, Pasternak GA, et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus; a systematic review and meta-analysis. Arch Intern Med. 2003;163:2594-2602.
17. Lalau JD, Race JM. Lactic acidosis in metformin therapy. Drugs. 1999;58(suppl 1):55-60.
18. Lalau JD, Race JM. Lactic acidosis in metformin-treated patients. Prognostic value of arterial lactate levels and plasma metformin concentrations. Drug Saf. 1999;20:377-384.
19. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854-865.
20. Erratum in: Lancet. 1998;352:1557.
21. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diabetes. 2003;27 (suppl 2):S1-S152.